Crossmark

Deriving safe limits for N-nitroso-bisoprolol by error-corrected next-generation sequencing (ecNGS) and benchmark dose (BMD) analysis, integrated with QM modeling and CYP-docking analysis

Crossref DOI link: https://doi.org/10.1007/s00204-025-04103-2

Published Online: 2025-06-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Simon, Stephanie https://orcid.org/0000-0002-2497-5211
Schlingemann, Jörg https://orcid.org/0000-0003-4799-1086
Johnson, George https://orcid.org/0000-0001-5643-9942
Brenneis, Christian https://orcid.org/0000-0003-1814-9535
Guessregen, Brunhilde https://orcid.org/0000-0003-3248-6247
Kostal, Jakub https://orcid.org/0000-0001-9727-0477
Dieckhoff, Jessica https://orcid.org/0009-0009-1908-5351
License Information

Text and Data Mining valid from 2025-06-11

Version of Record valid from 2025-06-11
More Information

Article History

Received: 2 May 2025

Accepted: 26 May 2025

First Online: 11 June 2025

Declarations

:

: The authors declare no conflict of interest, financial or otherwise. GJ is a consultant who evaluates the risks posed by pharmaceutical impurities. His clients did not influence the content of this manuscript.

: The manuscript does not contain clinical studies or patient data.

Document is current

Any future updates will be listed below